Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia.
TCL-1 expression is variable in CLL, and no study has examined its association with treatment response. We measured TCL-1 protein in CLL cells from 51 patients who then received pentostatin, cyclophosphamide, and rituximab. TCL-1 expression did not correlate with any pre-treatment characteristics. Lower TCL-1 levels were associated with higher probability of attaining flow cytometry-negative status post-treatment (52% versus 17%, p=0.046). Trends toward improved complete remission rate (49% versus 19%, p=0.064) and progression-free survival (medians: 33 versus 20 months, p=0.199) were noted with lower TCL-1 expression. These data suggest TCL-1 expression may help predict treatment outcome in CLL patients following chemoimmunotherapy, and examination in larger studies is warranted.
Ohio State University, Columbus, OH, United States.
Rebekah L
RL
Browning
Susan M
SM
Geyer
Amy J
AJ
Johnson
Diane F
DF
Jelinek
Renee C
RC
Tschumper
Timothy G
TG
Call
Tait D
TD
Shanafelt
Clive S
CS
Zent
Nancy D
ND
Bone
Gordon W
GW
Dewald
Thomas S
TS
Lin
Nyla A
NA
Heerema
Michael R
MR
Grever
Neil E
NE
Kay
John C
JC
Byrd
David M
DM
Lucas
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D016903:Drug Monitoring; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D018365:Neoplasm, Residual; D015649:Pentostatin / Q000627:therapeutic use; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D012074:Remission Induction / Q000379:methods; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D011518:Proto-Oncogene Proteins; C090851:TCL1A protein, human; D015649:Pentostatin; D000069283:Rituximab; D003520:Cyclophosphamide